RALY: A Protein Targeted for Neurodegenerative Disorders (G22913)

Target Name: RALY

NCBI ID: G22913

RALY

RALY: A Protein Targeted for Neurodegenerative Disorders

RNA binding proteins (RBP) are a class of proteins that play a critical role in regulating gene expression and have been implicated in a wide range of biological processes. One subclass of RBP is the autoantigenic (hnRNP-associated) group, which are proteins that contain a specific N-terminal region known as hnRNP. hnRNP is a protein that has been implicated in the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

One of the proteins that belongs to the hnRNP family is RALY, which is a RNA binding protein that has been shown to play a role in a wide range of biological processes. RALY is a protein that is expressed in many different tissues and cells, including brain, heart, and muscle. It is also highly expressed in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

One of the key functions of RALY is its ability to bind to specific RNA targets. This is accomplished through a process called RNA-protein interactions, which involve the formation of a protein-protein complex between the RNA target and RALY. Once RALY binds to its target RNA, it can interact with the RNA to regulate gene expression and promote the expression of other proteins.

In addition to its role in gene expression, RALY is also involved in the regulation of cellular processes such as cell adhesion, migration, and the cytoskeleton. It is also involved in the regulation of inflammation, as it has been shown to play a role in the development of various inflammatory diseases.

Given its involvement in a wide range of biological processes, RALY is a promising drug target. Researchers are currently working to develop compounds that can inhibit RALY's activity, with the goal of using these compounds as treatments for various diseases. For example, studies have shown that inhibiting RALY's activity can effectively treat neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug, RALY is also a potential biomarker for a wide range of diseases. Its expression is highly correlated with the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. This makes RALY an attractive candidate for use as a diagnostic or therapeutic target.

Overall, RALY is a protein that has the potential to revolutionize our understanding of the underlying mechanisms of various diseases. Its role in gene expression and cellular processes makes it an attractive candidate for use as a drug target, and its expression in a wide range of diseases makes it a valuable biomarker for diagnostic and therapeutic applications. Further research is needed to fully understand the full potential of RALY and its potential as a treatment or biomarker.

Protein Name: RALY Heterogeneous Nuclear Ribonucleoprotein

Functions: RNA-binding protein that acts as a transcriptional cofactor for cholesterol biosynthetic genes in the liver. Binds the lipid-responsive non-coding RNA LeXis and is required for LeXis-mediated effect on cholesterogenesis (By similarity). May be a heterogeneous nuclear ribonucleoprotein (hnRNP) (PubMed:9376072)

The "RALY Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RALY comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets